Sam Chun Dang Pharm. Co., Ltd
000250
🔒 Volume signal — free with login
🕒 Price Aug 29, 16:17 KST
Grade D · 19/100 — Defensive Pick
Investment caution signals
Automatic signals from DART filings and price trends. “Filing” items are detected from the last 180 days of electronic disclosures. Verify facts against the original filings/news. Not a buy/sell recommendation.
💰 Valuation at a glance
Yahoo FinancePrice ÷ EPS. Lower is cheaper vs earnings. Forward-earnings basis.
🎯 Fair-value estimate
OvervaluedCurrent ₩171,000 — vs fair value +233.3%
※ A theoretical estimate from an objective multiple model — not a price target or a buy/sell recommendation. Investment decisions and responsibility rest with the user.
📊 Price trend
Open in Multi-chart →Yahoo Finance🎯 7-metric analysis
Based on latest annual results
D19 pts
Value axes (P/E, P/B, EV) are growth- & profitability-adjusted — premium growth names aren’t pinned to zero. (Losses / negative equity stay 0.)
📈 Key metrics
Yahoo Finance🏢 Peer comparison
Pharma / BiotechSide by side with the largest names in the same sector. Green beats the sector median.
| Stock | P/E | P/B | ROE | Dividend |
|---|---|---|---|---|
| Sam Chun Dang Pharm. Co., LtdCurrent | 760.7× | 14.50× | 5.9% | — |
| ALTEOGEN Inc. | 157.1× | 50.00× | 25.8% | 0.1% |
| PharmaResearch Co., Ltd. |
🏦 Dividend vs deposit rate
This stock pays no dividend (or has no dividend data), so it isn't directly comparable to a deposit rate. It may be a growth name that relies on price appreciation instead.
As of: Bank of Korea weighted-avg deposit rate · 3.00% (2026-05)
📡 Technical signals
📊 Mixed moving averages · RSI 45 neutral · Dead cross
Above the moving averages means short-term bullish; below means bearish. RSI ≥ 70 is overbought and ≤ 30 is oversold.
🎮 What if you had bought?
If you'd bought Sam Chun Dang Pharm. Co., Ltd in the past, what would it be worth now? Play with the period and amount. (For reference · not a buy recommendation)
※ Simple close-price math, excluding fees, taxes and dividends. Past returns don’t guarantee future results.
📰 Related news
Source: Naver Finance (KR) · Yahoo Finance (US) · external article links
💼 Financial statements
Yahoo FinanceRecent annual
| Period | Revenue | Op. income | Net income | Op. margin |
|---|---|---|---|---|
| 2025 FY | ₩231.8B | ₩8.5B | ₩5.3B | 3.7% |
| 2024 FY | ₩210.9B | ₩2.6B | ₩-10.9B | 1.3% |
| 2023 FY | ₩192.7B | ₩9.6B | ₩-10.4B | 5.0% |
| 2022 FY | ₩177.3B | ₩12.2B | ₩5.8B | 6.9% |
Quarterly results (last 5 quarters)
📚 Metrics & scoringShow moreCollapse
🔎 Data sources & methodologyShow moreCollapse
Every score is auto-computed from the public data below. No manual adjustment.
| Item | Source | Method · update cadence |
|---|---|---|
| Price · volume · 52W | Yahoo Finance | Stored as-is · hourly intraday |
| Financials (revenue, profit, equity, debt) | Yahoo fundamentalsTimeSeries | Annual + quarterly reported · refreshed over ~1 week |
| Short-term (TTM) score | Computed (quarterly financials) | Sum of last 4 quarters + YoY momentum vs same quarter a year ago · daily |
| PER · PBR | Computed (KR) | Market cap ÷ latest annual net income / equity · N/A on loss or capital impairment |
| Dividend yield | Yahoo Finance | Annual dividend ÷ price · 0% if none |
| ROE · operating margin · debt ratio |